News

Larka Advises Keensight on CRO Axxam Acquisition

Larka Advises Keensight on CRO Axxam Acquisition

- Larka is delighted to announce it acted as the buy-side Commercial Due Diligence provider to support Keensight Capital on its acquisition of a majority stake in Axxam, a global-leading Contract Research Organization (CRO) based in Italy.

Larka Advises Cathay on its Investment in CRO Transcure

Larka Advises Cathay on its Investment in CRO Transcure

- Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France.

Larka Advises Merieux Equity Partners on its investment in Janvier Labs

Larka Advises Merieux Equity Partners on its investment in Janvier Labs

- Larka provides Merieux Equity Partners with a Commercial Due Diligence to support its investment in French BioPharma company Janvier Labs.
Larka Advises Elyan on CRO Oncodesign Acquisition Process

Larka Advises Elyan on CRO Oncodesign Acquisition Process

- Larka provides Elyan Partners with a Commercial Due Diligence to support the acquisition of CRO services Business Unit of Oncodesign, a leading French BioPharma company.

Larka Advises Gimv on CDMO BioConnection Investment Deal

Larka Advises Gimv on CDMO BioConnection Investment Deal

- Larka provides Gimv with a Technical Due Diligence and Operational Due Diligence to support its investment in leading Dutch bio-CDMO BioConnection.

Interview with: Yana Marmann

Interview with: Yana Marmann

- Fresh out of college and hired amid the COVID-19 pandemic, Yana saw in Larka an opportunity to shape a career within the BioPharma industry while evolving in a fast-paced and exciting environment.

Vendor Due Diligence for Afinum and SHS | evitria

Vendor Due Diligence for Afinum and SHS | evitria

- Larka is very pleased to announce that it’s M&A Unit performed the Vendor Commercial Due-Diligence to support Afinum’s exit process of evitria, a global leading service provider specialized in transient antibody expression.
Commercial Due Diligence for Keensight Capital | Symeres

Commercial Due Diligence for Keensight Capital | Symeres

- Larka is very proud to announce that it performed the Commercial-Due-Diligence for Keensight Capital on its acquisition of Symeres.
Commercial Due Diligence for Clean Biologics & Archimed | Biodextris

Commercial Due Diligence for Clean Biologics & Archimed | Biodextris

- Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed - on their acquisition of Biodextris.
Olivier Dumortier PhD Appointed as Business Development Manager

Olivier Dumortier PhD Appointed as Business Development Manager

- Prior to joining Larka’s Analysts team two years ago, Olivier did a PhD thesis in Belgium - exploring numerous models of metabolic diseases - then worked on non-coding RNA and regulation of cell metabolism and physiology in Canada and France for over a decade.
Maxime Clarhaut Appointed as Associate

Maxime Clarhaut Appointed as Associate

- Maxime has been working with Larka’s Analyst team for over two years now and keeps proving that dedication, combined with passion for Biotech and Pharma industry, lead to great achievements and value creation for our clients.
Lucas Leray joins Larka as Digital Marketing Manager

Lucas Leray joins Larka as Digital Marketing Manager

- Lucas will be a valuable asset for our Marketing & Sales Business Unit, as he brings strong expertise in both Research Marketing and Digital Marketing, particularly cruci
New Office

New Office

- As a result of a strong and continued growth in recent years, we are delighted to announce the opening of our new office in Nice.
New Brand Identity

New Brand Identity

- We are pleased to unveil our new logo and brand identity, reflecting the company’s values, culture and leadership position in the management consulting services and BPI.
New Website

New Website

- After months of combined development efforts from our digital marketing and IT teams, we are delighted to announce the official launch of Larka's brand new website.

Integrated Due Diligence for Cathay Capital | Biose

Integrated Due Diligence for Cathay Capital | Biose

- Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Cathay Capital.
Integrated Due Diligence for Keensight Capital | 3P Biopharmaceuticals

Integrated Due Diligence for Keensight Capital | 3P Biopharmaceuticals

- Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital.
Integrated Due Diligence for Archimed | Clean Cells

Integrated Due Diligence for Archimed | Clean Cells

- Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Archimed.
Integrated Due Diligence for Keensight Capital & ERES | Biovian

Integrated Due Diligence for Keensight Capital & ERES | Biovian

- Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital and ERES, the new shareholders of Biovian.